tbuckley/cabot-search huggingface dataset:
New viruses shake old paradigms
Authors: C.-Y. Wang
Journal: Journal of Clinical Investigation (2004)

Kaposi sarcoma–associated herpesvirus (KSHV) can establish latent infection in host cells. The latently infected cells can survive and proliferate with a few viral genes expressed. However, in some Kaposi sarcoma cells, KSHV undergoes a productive life cycle and causes cell lysis. A new study (see the related article beginning on page 124) demonstrates that, after KSHV infection or introduction of viral plasmids into host cells, viral DNA is rapidly lost. Lytic virus production with ensuing infections could balance the loss of the viral plasmids to maintain the virus in cancer cells.
Acta Chirurgica Scandinavica, Stockholm
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Monoclonal antibody against lymphocyte function-associated antigen 1 inhibits the formation of primary biliary cirrhosis-like lesions induced by murine graft-versus-host reaction
Authors: T Kimura
Journal: Hepatology (1996)

Interaction between intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 1 (LFA-1) might be involved in the pathogenesis of liver diseases. We investigated whether monoclonal antibodies (mAbs) against these two adhesion molecules could inhibit the formation of primary biliary cirrhosis (PBC)-like lesions in an animal model using graft-versus-host reaction (GVHR) with major histocompatibility complex class II disparity. PBC-like hepatic lesions such as cellular infiltration of portal area and nonsupprative destructive cholangitis (NSDC) were generated by injecting spleen T cells of C57BL/6 (B6) mice into (B6. C-H-2bm12 X B6) F1 mice. In the liver of these mice, increased number of LFA-1-positive cells and enhanced expression of ICAM-1 on sinusoidal endothelial cells and bile duct epithelial cells were observed immunohistochemically, when compared with F1 mice without GVHR. Hepatic lesions of these mAb-treated mice were almost completely inhibited in these mice compared with GVHR mice. Furthermore, we studied to determine which anti-LFA-1 mAb or anti-ICAM-1 mAb was essential to inhibit the hepatic lesions. Mice solely treated with anti-LFA-1 mAb showed significant inhibition of hepatic lesions, whereas treatment with anti-ICAM-1 mAb could not inhibit the lesions. Despite the inhibition of hepatic lesions, induction of GVHR and production of antimitochondrial antibodies were not impaired in mAb-treated mice. We conclude that LFA-1 mediates cell infiltration into the liver in this murine model of GVHR and suggest a possible therapeutic role of mAbs to this adhesion molecule in selective autoimmune liver diseases.
Medical care in the nursing home
Authors: J. G. Ouslander
Journal: JAMA (1989)

EVERY day more than 1.5 million Americans awaken in 1 of close to 20 000 nursing homes.<sup>1</sup>Some of these facilities provide excellent care, but the poor quality of care provided by many nursing homes has been repeatedly documented in the lay press, medical literature, and congressional testimony (<i>Los Angeles Times</i>. February 17, 1989; pt 1:3).<sup>2-4</sup>While the problems of many nursing home residents are more functional and psychosocial than medical,<sup>1,5</sup>the increasing acuity of medical conditions in this population since the implementation of the prospective payment system<sup>6,7</sup>demands that physicians be intimately involved in care provided in nursing homes. Yet, the majority of primary care physicians do not participate in the care of nursing home residents,<sup>8</sup>and very few of those who do provide care for substantial numbers of nursing home residents have received formal training in geriatric medicine or long-term care. Physician visits
Erratum
Journal: American Journal of Hematology (2020)

The authors thank a reader who noted errors in the case presentation, specifically, in the following sentence: "Her physical examination revealed petechiae, purpura, and hyperpigmented lesion on the trunk and extremities.Blood count analyses revealed a hemoglobin of 6.3 g/dL, mean corpuscular volume of 103 fL, leukocyte count of 810x10 9 /L, and platelet count of 2x10 9 /L.Readers are asked to please note the correct value of leucocyte count as 8.1x10 3 /μL (SI units: 8.1x10 9 /L) and the unit of thrombocyte level as platelet count of 2x10 3 /μL (SI units 2x10 9 /L).We apologize for this error.
Errata
Journal: British Journal of Dermatology (2013)

British Journal of DermatologyVolume 168, Issue 4 p. 914-914 Free Access Errata This article corrects the following: Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C R.B. Warren, A. Al-Ri Fai, Volume 168Issue 3British Journal of Dermatology pages: 461-462 First Published online: February 28, 2013 First published: 25 March 2013 https://doi.org/10.1111/bjd.12321AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the article by Warren et al.1 an author’s name was listed incorrectly. The author listed A. Al-Ri Fai as should have been listed as A. Al-Rifai. We apologise for this error. Reference 1Warren RB, Al-Ri Fai A. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C. Br J Dermatol2013; 168: 461– 462. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume168, Issue4April 2013Pages 914-914 ReferencesRelatedInformation
Dear President Clinton
Authors: V. R. Fuchs
Journal: JAMA (1993)

YOU are to be congratulated for recognizing the gravity of the crisis in health care. But please do not try to present a detailed plan for health care within 100 days. The problems are too complex and the public's understanding of them is too imperfect. Instead, you should present to the Congress and the public a clear statement of, and rationale for, your goals for health care and your basic approach to achieving these goals. If your goals include covering all Americans for a package of essential services, sharing the costs of this package fairly, and slowing significantly the rate of growth of health expenditures, do not imagine that incremental reform of the present system can do the job. Only comprehensive change in finance and organization has a chance of success. The public, however, is not ready for comprehensive change. Most Americans have health insurance. Most Americans are satisfied with
Traité pratique d'orthopédie.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doctors' Pay
Authors: J. M. Finnerty
Journal: BMJ (1964)

<i>Neisseria meningitidis</i> is a major cause of sepsis and/or meningitis. These bacteria normally cause disease only in humans, however, mice expressing human CD46 are susceptible to meningococcal disease. To explain the sensitivity of CD46 transgenic mice to meningococci, we evaluated early immune responses. Stimulation of TNF, IL-6, and IL-10 was stronger in CD46 transgenic mice compared with nontransgenic mice, and resembled human responses. In CD46 transgenic mice, bacterial clearance in blood started at later time points, and neutrophil numbers in blood were lower compared with nontransgenic mice. Further, elevated levels of activated microglia cells and cyclooxygenase-2 were observed in brain of infected CD46 transgenic mice. Intraperitoneal administration of meningococci lead to increased levels of macrophages only in the i.p. cavity of CD46 transgenic mice. Most of the responses were impaired or absent using LPS-deficient meningococci, showing the importance of LPS in the early immune response to meningococcal infection. Taken together, these data demonstrate that responses in mice expressing human CD46 mimic human meningococcal disease in many aspects, and demonstrate novel important links between CD46 and the innate immune system.
COLLOID PSEUDOMILIUM.
Authors: JOHN R. G. AGIUS
Journal: British Journal of Dermatology (1963)

Journal Article COLLOID PSEUDOMILIUM. Get access JOHN R. G. AGIUS, B.Sc., M.D., D.C.H.(LOND.) JOHN R. G. AGIUS, B.Sc., M.D., D.C.H.(LOND.) The Department of Medicine, Royal University of Malta, Valetta Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 75, Issue 2, 1 February 1963, Pages 55–59, https://doi.org/10.1111/j.1365-2133.1963.tb13938.x Published: 01 February 1963
A review of phase 3 clinical trials of CDK4/6 inhibitor combination therapy in premenopausal women.
Authors: Denise A. Yardley
Journal: Journal of Clinical Oncology (2018)

e13057 Background: Clinical guidelines for the treatment of hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC) patients are similar regardless of menopausal status, except for ovarian suppression. However, premenopausal women commonly present with a more aggressive phenotype and distinct underlying disease biology that is unaffected by ovarian suppression. Methods: We compared published trial designs, baseline characteristics, and efficacy and safety results of Phase 3 trials of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors that included premenopausal women with HR+, HER2− ABC. Results: The MONALEESA-7 trial (NCT02278120) investigated ribociclib (or placebo) + a nonsteroidal aromatase inhibitor or tamoxifen + goserelin ovarian suppression in premenopausal women with ≤1 line of prior chemotherapy for ABC (N = 672); 40% had de novo ABC. Median progression-free survival (PFS) was 23.8 vs 13.0 months with ribociclib (n = 335) vs placebo (n = 337). Common ( > 30%) adverse events (AEs) in the ribociclib group were neutropenia (75.8%), hot flash (34.0%), nausea (31.6%), and leukopenia (31.3%). In the PALOMA-3 trial (NCT01942135), 108 of 521 patients were premenopausal, were treated with palbociclib (or placebo) + fulvestrant + goserelin, and had prior therapy for ABC (75%) or early (25%). Median PFS in premenopausal patients with palbociclib (n = 72) vs placebo (n = 36) was 9.5 vs 5.6 months; common ( > 40%) AEs in the palbociclib group were neutropenia (85.9%), leukopenia (56.3%), infections (pooled; 47.9%), and nausea (40.8%). In the MONARCH 2 trial (NCT02107703), 669 women without prior chemotherapy for ABC received abemaciclib (or placebo) + fulvestrant + goserelin. Among all patients, 59% and 38% had 0 and 1 prior lines of ET for metastatic disease. In premenopausal women (abemaciclib, n = 72; placebo, n = 42), abemaciclib prolonged PFS with a hazard ratio of 0.415 (95% CI, 0.246–0.698). Conclusions: While trial and patient characteristics differ substantially, safety and efficacy established in the MONALEESA-7 trial of premenopausal women and premenopausal subsets of the PALOMA-3 and MONARCH 2 trials support using CDK4/6 inhibitor combination therapy in these patients.
THE ALCOHOL QUESTION.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Toxicology
Authors: Lewis R. Goldfrank
Journal: JAMA (1992)

Medical toxicology is the study of physical and chemical agents and their effects on subcellular structures, living cells, and organisms. These effects define a toxicologic problem and are studied from dose-response and mechanistic perspectives. The field of medical toxicology is being considered for subspecialty recognition by the American Board of Medical Specialists. Post-residency fellowships in medical toxicology have been developed at 21 major medical centers and universities. The body of knowledge that is medical toxicology includes the clinical manifestations, differential diagnoses, and treatments of acute poisoning (including accidental, suicidal, and substance abuse), acute and chronic exposure to toxins in the workplace, and exposure to environmental toxins. Medical toxicologists working in the country's regional poison centers and teaching hospitals apply this body of knowledge as they care for patients of all ages and backgrounds. The Institute of Medicine has recommended that all primary care physicians improve awareness, understanding, and management of
The Hypothalamus
Authors: Vernon H. Mark
Journal: JAMA (1971)

This monograph was the result of the symposium which focused on the integration of endocrine and nonendocrine mechanisms in the hypothalamus. In general terms, it is compared to the symposium on the hypothalamus which was held in New York, in December 1939, under the auspices of the Association for Research in Nervous and Mental Disease, and published in their 20th volume. This comparison is not really apt, however, since in the 1939 symposium less than a half dozen papers out of 35 dealt with endocrine aspects of the hypothalamus, and in the present volume, two thirds of the 38 papers are chiefly concerned with this topic. The present volume is notable for a thorough discussion of the mechanisms controlling the secretions of the anterior and posterior pituitary hormones, the releasing factors as well as the inhibiting factors and the possible role of long and short loop feedback mechanisms. Also there
Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
Authors: Pascal Hammel, Rossana Berardi, Eric Van Cutsem, Jaime Feliu, Richard Greil, Harpreet Singh Wasan, Jean-Philippe Metges, Peter Nygren, Pia J. Osterlund, Vibeke Parner, Thomas Seufferlein, Anu Gupta, Sophie Salesse, Nigel Biswasbaldwin, Ayman Ibrahim, Hagop Youssoufian, Iman El-Hariry, Manuel Hidalgo
Journal: Journal of Clinical Oncology (2019)

TPS471 Background: Second-line treatment options for advanced pancreatic adenocarcinoma are currently limited. Eryaspase, asparaginase (ASNase) encapsulated in red blood cells (RBCs) is an investigational product under development. Following infusion, asparagine and glutamine are actively transported into RBCs where they are hydrolyzed by the encapsulated ASNase. We have recently reported the outcome of a randomized Phase 2b study inpatients with advanced pancreatic cancer whose disease progressed following first-line treatment(NCT02195180). Eryaspase in combination with gemcitabine monotherapy or FOLFOX combination therapy improved overall survival (OS) and progression free survival (PFS). The safety profile of eryaspase was acceptable. The results of this Phase 2b study provided a rationale for initiating this confirmatory Phase 3 pivotal trial (TRYbeCA-1). Methods: TRYbeCA-1 is an international, randomized, open-label Phase 3 trial (N = ~500) of eryaspase combined with chemotherapy in patients with adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease. Patients are randomized in a 1:1 ratio to receive gemcitabine/abraxane or irinotecan-based therapy (FOLFIRI [FOLinic acid-Fluorouracil-IRInotecan regimen] or irinotecan liposome injection/5-fluorouracil/leucovorin) with or without eryaspase, administered as IV infusion on Day 1 and Day 15 of each 4-week cycle. Key eligibility criteria include performance status 0 or 1; stage IV disease; documented evidence of disease progression; available tumor tissue; and adequate organ function. The primary endpoint is OS. Key secondary endpoints include PFS and objective response rate, safety, quality of life, pharmacokinetics and pharmacodynamics, and biomarker research. An HR in OS of 0.725 is being targeted representing a conservative estimate based on the P2b data and is viewed as being highly clinically relevant. An IDMC will be established to review safety at regular intervals and to review efficacy data at the planned interim and final analyses. Clinical trial information: NCT03665441.
Prenatal Life
Authors: David C. Duncombe
Journal: JAMA (1978)

<h3>To the Editor.—</h3> The article by Hans O. Tiefel, PhD (239:2263, 1978), makes an important point: there can be legitimate moral reasons for either preserving or destroying prenatal life without having to regard the embryo or fetus as less than human. Tiefel concludes by hinting that this position might make sense even "to those who are in doubt as to whether the unborn are human beings." As one of those in doubt, who deems less than compelling the author's subsequent reasons for believing that human life begins at conception, I find, nevertheless, that his main position still makes sense. With the simple addition of an agnostic (<i>agnoeo</i>, not to know) disclaimer, Tiefel's position might read as follows: Since we do not know when human life begins, it might begin at conception; so let us make our decisions on the basis of other life values—much as medical triage is done. Thus, in
Tc-99m MDP Accumulation in Lymphoma
Authors: A. MALPANI, Y. TAKAMIA, C. BEKERMAN, T. BRANDT, S. PINSKY, M. BLEND
Journal: Clinical Nuclear Medicine (1990)

MALPANI, A. M.D.; TAKAMIA, Y. C.N.M.T*; BEKERMAN, C. M.D.; BRANDT, T. M.D.; PINSKY, S. M.D.; BLEND, M. Ph.D., D.O. Author Information
Medico-Legal
Journal: BMJ (1929)

the number of animals they proposed to use for experi- ments.The Home Office had no record of the number of animalsused as distinct from the number of experiments per- formed under the Act in 1927, nor of the number of dogs and cats used for* experiments in 1927 under Certificate B, plus E E. Section 5 of the Act, which governed Certificate E E, did not distinguish between cats and dogs.On July 15th Mr. MAcDONALD told Sir R.
The Serum Diagnosis of Diseases.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1954)

Unpleasant Sensations and Thundery Weather Q.-I should be grateful for information regarding the cause of those unpleasant vasomotor effects from which some people suffer in thundery weather or whenever the atmo- spheric pressure varies widely within short periods of time.The ones particularly for which advice would be appreciated are headache, nausea, diz-iness, and the peculiar sinking
Authors' Response
Authors: Michael Domjan, Brian Cusato, Ronald Villarreal
Journal: Behavioral and Brain Sciences (2004)

For the authors' responses to comments similar to those expressed here by Balsam &amp; Drew , please see: M. Domjan, B. Cusato, &amp; R. Villarreal (2000). Extensions, elaborations, and explanations of the role of evolution and learning in the control of social behavior. BBS 23(2):269–82. [Authors' Response to first round of commentary.]